Molecular profiling-based decision for targeted therapies in IDH wild-type glioblastoma

Abstract

Background Molecular profiling allows tumor classification as well as assessment of diagnostic, prognostic, and treatment-related molecular changes. Translation into clinical practice and relevance for patients has not been demonstrated yet. Methods We analyzed clinical and molecular data of isocitrate dehydrogenase wild-type glioblastoma patients with sufficient clinical follow-up from the Heidelberg Neuro-Oncology Center and with molecular analysis of tumor tissue that consisted of DNA methylation array data, genome-scale copy number variations, gene panel sequencing, and partly mTOR immunohistochemistry between October 2014 and April 2018. Results Of 536 patients screened, molecular assessment was performed in 253 patients (47%) in a prospective routine clinical setting with further clinical appointments. Therapy decision was directly based on the molecular assessment in 97 (38%) patients. Of these, genetic information from MGMT (n = 68), EGFR (n = 7), CDKN2A/B (n = 8), alterations of the PI3K–AKT–mTOR pathway (n = 5), and BRAF (n = 3) have been the most frequently used for decision making with a positive overall survival signal for patients with glioblastoma harboring an unmethylated MGMT promoter treated according to the molecular assignment. Based on detected molecular alterations and possible targeted therapies, we generated an automated web-based prioritization algorithm. Conclusion Molecular decision making in clinical practice was mainly driven by MGMT promoter status in elderly patients and study inclusion criteria. A reasonable number of patients have been treated based on other molecular aberrations. This study prepares for complex molecular decisions in a routine clinical decision making.

Diagnostic accuracy of 1p/19q codeletion tests in oligodendroglioma: A comprehensive meta‐analysis based on a Cochrane systematic review

“…It is primarily used to establish epigenetic profiles of brain tumours, but the array data also generate a copy number profile with the added benefit of visualising chromosomal aberrations including 1p/19q codeletion [75, 76, 78–80]. This has been reported in two comparative studies [81, 82].…”

Personalised therapeutic approaches to glioblastoma: A systematic review

“…Personalised chemotherapy regimens informed by in vitro drug sensitivity testing on autologous resected tumour cells appeared beneficial in 2 non-randomised trials studying a total of 105 patients (76,77). However, 3 non-randomised trials using genomic-profiling to guide personalised molecular therapy had mixed survival results (78)(79)(80).…”

Neurosurgery's Impact on Neuro-Oncology—“Can We Do Better?”—Lessons Learned Over 50 Years

“…41 Identification and characterization of specific GBM molecular features has implications for diagnosis, prognosis, and prediction of treatment response and increasingly can inform our surgical objectives as well, ushering us into the molecular era of neuro-oncology. [42][43][44] Much effort has been invested in identifying and characterizing specific mutations that may serve as therapeutic targets in primary or recurrent glioblastoma including epidermal growth factor receptor (EGFR), vascular endothelial growth factor (VEGF), the tyrosine protein kinase mTOR, fibroblast growth factor receptor (FGFR), the proto-oncogene BRAF, and other genes. 45 Although it is known that tumors with a methylated methylguaninedeoxyribonucleic acid methyltransferase (MGMT) promoter region will have an enhanced response to temozolomide and better prognosis, presumably because of downregulation of the MGMT gene transcription by hypermethylation, this has not translated into new therapies for patients.…”